Comparative Pharmacology
Head-to-head clinical analysis: CORTONE versus XHANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTONE versus XHANCE.
CORTONE vs XHANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, leading to decreased inflammation through inhibition of phospholipase A2, reduced cytokine production, and suppression of immune cell migration.
XHANCE (fluticasone propionate) is an anti-inflammatory corticosteroid that inhibits multiple inflammatory cell types and mediators (e.g., histamine, leukotrienes, cytokines) involved in nasal and sinus inflammation. It reduces nasal polyp size and nasal congestion.
Oral: 25-300 mg daily in 1-4 divided doses; typical initial dose 150-300 mg daily. IM/IV: 100-500 mg every 6-12 hours.
1 spray (93 mcg fluticasone propionate) per nostril twice daily (total daily dose 372 mcg). Intranasal route.
None Documented
None Documented
Terminal half-life: 8-12 hours (cortisone) but cortisone is a prodrug; active metabolite cortisol has half-life 1.5-2 hours. Clinical context: duration of action 8-12 hours due to prolonged receptor occupancy.
Terminal half-life is approximately 2-3 hours; short half-life supports twice-daily dosing for sustained local effect.
Renal: ~90% as metabolites (glucuronides and sulfates), ~5% unchanged; biliary/fecal: ~5%.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% of the dose as unchanged drug; fecal excretion is minimal.
Category C
Category C
Corticosteroid
Corticosteroid